Increased blood absolute T-cell counts following treatment
Patient . | . | Absolute T-cell count (/μL)4-150 . | % Increase . | Week . | |
---|---|---|---|---|---|
Day 0 . | Peak . | ||||
003 | CD3+ | 1780 | 5440 | 206 | 1 |
CD4+ | 680 | 1250 | 84 | ||
CD8+ | 770 | 3810 | 395 | ||
004 | CD3+ | 220 | 1280 | 482 | 3 |
CD4+ | 60 | 600 | 900 | ||
CD8+ | 140 | 560 | 300 | ||
005 | CD3+ | 160 | 530 | 231 | 4 |
CD4+ | 40 | 200 | 400 | ||
CD8+ | 120 | 240 | 100 | ||
006 | CD3+ | 910 | 4420 | 386 | 1 |
CD4+ | 300 | 590 | 97 | ||
CD8+ | 520 | 3410 | 556 | ||
007 | CD3+ | 2240 | 4680 | 109 | 3 |
CD4+ | 1120 | 3340 | 198 | ||
CD8+ | 1000 | 1220 | 22 | ||
008 | CD3+ | 3710 | 4990 | 35 | 1 |
CD4+ | 460 | 2290 | 398 | ||
CD8+ | 930 | 2040 | 119 | ||
009 | CD3+ | 1080 | 5530 | 412 | 1 |
CD4+ | 300 | 550 | 83 | ||
CD8+ | 350 | 4430 | 1166 | ||
010 | CD3+ | 1740 | 5500 | 216 | 4 |
CD4+ | 520 | 1670 | 221 | ||
CD8+ | 1040 | 3110 | 199 | ||
011 | CD3+ | 2850 | 5610 | 97 | 2 |
CD4+ | 1580 | 2010 | 27 | ||
CD8+ | 1580 | 3010 | 91 |
Patient . | . | Absolute T-cell count (/μL)4-150 . | % Increase . | Week . | |
---|---|---|---|---|---|
Day 0 . | Peak . | ||||
003 | CD3+ | 1780 | 5440 | 206 | 1 |
CD4+ | 680 | 1250 | 84 | ||
CD8+ | 770 | 3810 | 395 | ||
004 | CD3+ | 220 | 1280 | 482 | 3 |
CD4+ | 60 | 600 | 900 | ||
CD8+ | 140 | 560 | 300 | ||
005 | CD3+ | 160 | 530 | 231 | 4 |
CD4+ | 40 | 200 | 400 | ||
CD8+ | 120 | 240 | 100 | ||
006 | CD3+ | 910 | 4420 | 386 | 1 |
CD4+ | 300 | 590 | 97 | ||
CD8+ | 520 | 3410 | 556 | ||
007 | CD3+ | 2240 | 4680 | 109 | 3 |
CD4+ | 1120 | 3340 | 198 | ||
CD8+ | 1000 | 1220 | 22 | ||
008 | CD3+ | 3710 | 4990 | 35 | 1 |
CD4+ | 460 | 2290 | 398 | ||
CD8+ | 930 | 2040 | 119 | ||
009 | CD3+ | 1080 | 5530 | 412 | 1 |
CD4+ | 300 | 550 | 83 | ||
CD8+ | 350 | 4430 | 1166 | ||
010 | CD3+ | 1740 | 5500 | 216 | 4 |
CD4+ | 520 | 1670 | 221 | ||
CD8+ | 1040 | 3110 | 199 | ||
011 | CD3+ | 2850 | 5610 | 97 | 2 |
CD4+ | 1580 | 2010 | 27 | ||
CD8+ | 1580 | 3010 | 91 |
Blood was collected from patients preinfusion (day 0), 1, 2, 3, 4, 8, and 12 weeks following treatment with Ad-CD154-CLL cells. A complete blood count with manual differential was performed and mononuclear cells were isolated by Ficoll-Hypaque density centrifugation. Mononuclear cells were stained with fluorochrome-labeled mouse antihuman CD3, CD4, and CD8 monoclonal antibody and isotype control then analyzed by flow cytometry to obtain percent CD3+, CD4+, and CD8+ cells. Absolute T-cell counts were calculated by multiplying absolute mononuclear cell count times percent CD3+, CD4+, or CD8+ cells. The peak time and absolute T-cell count are depicted.